Biden administration doles out $100M to research drug-resistant infectionsnews2023-09-27T19:43:15+00:00September 27th, 2023|Endpoints News|
Bristol Myers teams with social media influencer and singer to spark rare heart condition awarenessnews2023-09-27T19:30:52+00:00September 27th, 2023|Endpoints News|
Amgen readies PhIII trial for first Opdivo biosimilar, with launch unlikely before 2028news2023-09-27T19:26:54+00:00September 27th, 2023|Endpoints News|
FDA approves decade-old Pfizer drug for rare childhood leukemianews2023-09-27T17:53:26+00:00September 27th, 2023|Endpoints News|
Bluebird tweaks partnership with Lonza to boost Zynteglo, Skysona manufacturing capacitynews2023-09-27T16:52:42+00:00September 27th, 2023|Endpoints News|
Boehringer agrees to comply with CMS’ price negotiations over blockbuster Jardiancenews2023-09-27T16:48:55+00:00September 27th, 2023|Endpoints News|
FDA+ roundup: Agency reopens AI discussion paper for comments amid two-day workshopnews2023-09-27T16:40:13+00:00September 27th, 2023|Endpoints News|
Cardiff’s stock jumps after sharing promising PhII data for its PLK1 inhibitor onvansertib in pancreatic cancernews2023-09-27T15:26:12+00:00September 27th, 2023|Endpoints News|
Théa won’t buy ProQR’s ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in Octobernews2023-09-27T15:16:23+00:00September 27th, 2023|Endpoints News|
Gilead stops another CD47 study, this time in acute myeloid leukemianews2023-09-27T14:21:01+00:00September 27th, 2023|Endpoints News|
